Associated Genetic Biomarkers
NCI Definition: A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS). 
There are 9 clinical trials for Kaposi sarcoma, of which 8 are open and 1 is completed or closed. Of the trials that contain Kaposi sarcoma as an inclusion criterion, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open).
Nivolumab, pembrolizumab, and nhs-il12 are the most common interventions in Kaposi sarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.